Liver function tested for new fatty liver drug
NCT ID NCT05917938
First seen Feb 19, 2026 · Last updated May 15, 2026 · Updated 11 times
Summary
This study tested a single injection of a new medicine (NNC0194-0499) for fatty liver disease in 33 adults with various levels of liver function, including healthy volunteers. Researchers measured how the drug moves through the body and checked safety. The goal was to understand dosing for people with liver impairment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APEX Research
München, 81241, Germany
-
Cardiomedicum Sp. z o.o.
Krakow, 30-002, Poland
-
Summit Clinical Research s.r.o.
Bratislava, 83101, Slovakia
-
Summit Clinical Research s.r.o.
Malacky, 901 22, Slovakia
-
Uniwersyteckie Centrum Kliniczne (UCK)
Gdansk, 80-214, Poland
Conditions
Explore the condition pages connected to this study.